So tell us a little bit about your career journey and how a Parkinson's disease research project turned into a career in licensing.

Absolutely.

So when I first got started after college, I was working as a lab tech in Chris Bishop's lab at Binghamton University.

I had volunteered with his lab during my undergrad, but during the few years afterwards, we were exploring just different approaches to treating dyskinesia and Parkinson's disease.

It was during that time he found that a particular class of FDA-approved antidepressants did a really great job of managing the dyskinesia, a motor symptom within Parkinson's.

And so it was at that time that Tech Transfer invited me to participate in a regional I-Corps course just to better understand the market landscape.

At my PI's request, I had focused my 20 interviews at pharma companies working in neurology because the two of us had expected that they were just going to buy our patents right then and there and that that would be the whole quick and easy process.

And why did you think framing it this way makes more sense than splitting things out by therapeutic area, whether it's cancer, neuroscience, biologics, etc.? ?

Is he your favorite to win the Cy Young?

He's been lights out pretty much, you know, more than anyone could have hoped for when they signed Cease this offseason.

If he keeps throwing in, you know, keeps mixing in, flirting with no hitters almost every time he takes the ball, it's... it's tough to argue, but camp Schuylter on the Yankees, he's been, you know, equally as good or even better.

It's you can't really go wrong with either.

Um, you look at their stats, they're just so close.

ERA Schuylter has a slight advantage, whip slight advantage for Schuylter, um, you know, FIP uh which you know takes out kind of the defense and what the pitcher can't control uh Cease has a slight advantage there War Cease slight advantage um so really it's just been such a good battle uh between two high-end arms in the American League East uh 27 starts for Schlittler compared to the 24 from Cease because of his brief IL stint uh so Schlittler has the innings advantage um but then Cease has the strikeouts advantage so I think right now I would lean Schlittler at the moment, but Cease has certainly closed the gap.

He's probably got six or seven starts left.

If this team, like the playoff push doesn't work out, they don't make the playoff in the offseason, what are you kind of hoping for the Blue Jays to do?

What's currently commanding most of your attention as a leader right now?

Well, there's a couple things.

One is this change of workforce that we're dealing with.

You know, in the, in the rural area, our bench strength is, is pretty limited to begin with, and so, you know, struggling to find those, those well-seasoned leaders that wanna move to the rural area or growing our own, which we have to do a lot.

So, so workforce is one, and then of course, you know, things with payers.

Payers right now, um, especially advantage plans, I tell my board, uh, trustees there's no advantage to the advantage plans for the hospitals.

Um, so we're, we're educating our community about, uh, what they're buying in those advantage plans, whose responsibility it is, and, um, how, how they can get the best care for what they purchased.

W- you might've, you might've touched on, on some of this, but what recent decision or pivot required the most leadership conviction from you as an individual, particularly when it came to aligning people, you know, bringing people together a- and, and resources or capabilities?